US 12,465,599 B2
Compositions for the treatment of hypertension
Anthony Rodgers, Newtown (AU); and Stephen Macmahon, Newtown (AU)
Assigned to THE GEORGE INSTITUTE FOR GLOBAL HEALTH, Newtown (AU)
Filed by The George Institute for Global Health, Sydney (AU)
Filed on Apr. 1, 2025, as Appl. No. 19/097,314.
Application 19/097,314 is a continuation of application No. 18/446,268, filed on Aug. 8, 2023, granted, now 12,285,415.
Application 18/446,268 is a continuation of application No. 17/932,982, filed on Sep. 16, 2022, granted, now 12,102,623, issued on Oct. 1, 2024.
Application 17/932,982 is a continuation of application No. 17/014,358, filed on Sep. 8, 2020, granted, now 11,478,462, issued on Oct. 25, 2022.
Application 17/014,358 is a continuation of application No. 16/393,774, filed on Apr. 24, 2019, granted, now 10,799,487, issued on Oct. 13, 2020.
Application 16/393,774 is a continuation of application No. 15/919,923, filed on Mar. 13, 2018, granted, now 10,322,117, issued on Jun. 18, 2019.
Application 15/919,923 is a continuation of application No. PCT/IB2018/000083, filed on Jan. 23, 2018.
Claims priority of provisional application 62/450,324, filed on Jan. 25, 2017.
Prior Publication US 2025/0312325 A1, Oct. 9, 2025
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4422 (2006.01); A61K 31/277 (2006.01); A61K 31/382 (2006.01); A61K 31/40 (2006.01); A61K 31/4035 (2006.01); A61K 31/404 (2006.01); A61K 31/41 (2006.01); A61K 31/4178 (2006.01); A61K 31/4184 (2006.01); A61K 31/4418 (2006.01); A61K 31/495 (2006.01); A61K 31/517 (2006.01); A61K 31/549 (2006.01); A61K 31/554 (2006.01); A61P 9/12 (2006.01)
CPC A61K 31/4422 (2013.01) [A61K 31/277 (2013.01); A61K 31/382 (2013.01); A61K 31/40 (2013.01); A61K 31/4035 (2013.01); A61K 31/404 (2013.01); A61K 31/41 (2013.01); A61K 31/4178 (2013.01); A61K 31/4184 (2013.01); A61K 31/4418 (2013.01); A61K 31/495 (2013.01); A61K 31/517 (2013.01); A61K 31/549 (2013.01); A61K 31/554 (2013.01); A61P 9/12 (2018.01)] 16 Claims
 
1. A pharmaceutical composition comprising:
(a) telmisartan;
(b) indapamide; and
(c) amlodipine besylate,
wherein the dose of telmisartan is from about 8 mg to about 12 mg, the dose of indapamide is from about 0.5 mg to about 0.75 mg, and the dose of amlodipine besylate is from about EQ 1 mg base to about EQ 1.5 mg base or from about EQ 1.5 mg base to about EQ 2 mg base; and wherein the pharmaceutical composition is free of beta-blocker.